Dica

Quick links to important sections

Dica

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dica

What is Dica? An Overview

Property Description
Active Ingredients Magnesium Hydroxide and Serratiopeptidase
Form Oral (Tablet or Suspension)
Pharmacological Class Fixed-Dose Combination Drug, Antacid/Saline Laxative, and Systemic Anti-inflammatory Enzyme
Common Use (General) Relief of acid indigestion and support for reducing swelling
Origin Combined Synthetic/Biological

What Type of Medicine is Dica? A Combination Product Definition

Dica is classified as a fixed-dose combination drug, integrating two active pharmaceutical ingredients with distinct pharmacological actions into a single oral preparation. This structure positions it as a polypharmaceutical agent, which means it is designed to achieve simultaneous therapeutic effects by combining two substances. The medicine is administered orally, typically in solid forms like a Tablet, or sometimes as an oral liquid Suspension. The high-level pharmacological class of Dica is dual: it functions as a Gastrointestinal Modifier (Antacid and Saline Laxative) and a Systemic Anti-inflammatory Enzyme agent.


Composition and Origin: Magnesium Hydroxide and Serratiopeptidase

Dica’s composition includes the inorganic chemical compound Magnesium Hydroxide and the derived biological substance Serratiopeptidase. The first component, Magnesium Hydroxide (Magnesium Dihydroxide), is a known inorganic chemical that functions as an antacid by neutralizing stomach acid. The second component, Serratiopeptidase (Serrapeptase), is a proteolytic enzyme that is derived from a species of Serratia bacteria, classifying the overall product as a Combined Synthetic/Biological entity. Research has noted Serratiopeptidase's role in supporting the resolution of inflammation, an action that has been clinically recognized for its anti-edematous properties.


General Purpose: Dual Action on Acid and Inflammation

The general purpose of Dica is to provide simultaneous relief by managing gastrointestinal acid discomfort and addressing swelling associated with inflammation. This dual therapeutic focus utilizes the Magnesium Hydroxide component to manage the symptoms of gastric acid issues and encourage intestinal function. Concurrently, the Serratiopeptidase component, acting as a proteolytic enzyme, is purposed to facilitate the breakdown and clearance of inflammatory byproducts. This combination strategy provides a comprehensive approach to managing both acute digestive discomfort and underlying systemic inflammatory conditions.

Regulatory References

  1. Magnesium Hydroxide Drug Information

What side effects are possible with Dica?

Possible Side Effects and Safety Information

The safety profile for Dica, which combines Magnesium Hydroxide and Serratiopeptidase, is organized by regulatory bodies according to the type and frequency of documented adverse reactions. Information is based strictly on governmental regulatory labeling.


Official Adverse Reactions and Frequencies

Adverse reactions are primarily classified by system-organ classes, with Gastrointestinal Disorders being the most commonly reported. Common adverse effects, which are expected, include diarrhea and abdominal discomfort due to the action of the saline laxative component. Uncommon or rare effects include nausea, vomiting, and skin reactions such as rash.

Classification Common Side Effects Rare/Serious Adverse Reactions
System-Organ Class Gastrointestinal Disorders Metabolism/Nutrition, Blood/Lymphatic
Examples Diarrhea, Abdominal Discomfort Hypermagnesemia, Hemorrhage/Coagulation Defects

Serious Safety Considerations

The most serious regulatory concerns include the rare but potentially systemic effects of Hypermagnesemia (excess magnesium in the blood), categorized under Metabolism and Nutrition Disorders. This risk is especially noted in the official labeling for patients with renal impairment. The enzyme component, Serratiopeptidase, also carries a rare, documented risk of coagulation abnormalities and hemorrhage, classified under Blood and Lymphatic System Disorders.

Safety Constraints and Patterns

The product is contraindicated for use in individuals with severe renal failure due to the significantly increased risk of Hypermagnesemia. Time-related safety patterns indicate that common gastrointestinal effects are more frequently observed at the start of treatment or following dose adjustments.

Overdose and Emergency Response

Overdose and When to Seek Help

The Overdosage section of the regulatory labeling for Dica indicates that ingestion or administration of doses substantially exceeding the maximum recommended daily dose can lead to a serious and potentially life-threatening condition. Immediate emergency medical assistance must be sought in the event of any known or suspected overdose. Do not attempt to manage an overdose at home.

Overdose presentations typically reflect exaggerated pharmacological effects and may manifest as severe symptoms impacting the Cardiovascular and Central Nervous Systems. Due to the serious nature of potential outcomes, this toxicity is officially classified as carrying a high risk of adverse events.

The official guidance emphasizes that management of a Dica overdose is supportive and symptomatic only, as no specific antidote is available. Medical professionals will institute general supportive measures, which include continuous monitoring of vital signs and close observation of the patient's clinical status to manage the manifestations of toxicity. The immediate priority is stabilization under medical supervision. The regulatory information stresses the seriousness of this event and the necessity of immediate specialized care.

Therapeutic Uses of Dica

What Dica Treats: Main Uses and Benefits

Dica is commonly used in conditions presenting with systemic or localized discomfort linked to chronic joint issues. It is relevant in clinical settings marked by increased discomfort and functional strain. This medication is commonly used to help with symptoms associated with chronic conditions like Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

It helps address symptom clusters related to physical discomfort (aching, pain), inflammatory or irritative states (swelling, tenderness), and functional stability (stiffness, reduced mobility). This provides support that helps ease the overall symptom burden, particularly during phases when symptoms become more noticeable.

“This approach is commonly used in conditions characterized by periods of heightened symptoms that interfere with daily functioning.”

The medication is applied in clinical settings that involve acute or unstable symptom patterns, where short-term symptomatic assistance is needed to help patients cope more steadily with symptom fluctuations.


Quick Fact: Support for Persistent Discomfort Symptoms Dica supports the patient during difficult episodes by easing distress associated with chronic pain and inflammation, contributing to improved day-to-day comfort.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Dica — Official Regulatory Information

The eligibility profile for Dica (Magnesium Hydroxide + Serratiopeptidase) is strictly defined by official regulatory documentation, focusing on absolute exclusions and specific restrictions.


Eligibility Scope

Category Official Regulatory Classification
Populations for whom use is allowed Adults (18 years and older).
Populations for whom use is not recommended Pregnant and Breastfeeding individuals; Children under 12 years of age.
Populations for whom use is contraindicated Patients with known Hypersensitivity to any component; Severe Renal Impairment; known Bleeding Disorders or use of Anticoagulant Therapy; Acute Abdominal Conditions or Intestinal Obstruction.

Key Eligibility Rules

  • Use is contraindicated in patients with severe renal impairment due to the risk of magnesium accumulation and in patients with bleeding disorders due to the systemic enzyme component.
  • The medicine is generally not recommended in children under 12 years as safety and efficacy are not established for the combination in this age group.
  • Use with caution is advised for older adults and those with moderate renal impairment to mitigate the risk of adverse effects associated with impaired drug clearance.

Connection to the overall eligibility profile:

Regulatory documents define eligibility by establishing formal contraindications tied to organ function and coagulation status, and by specifying populations where use is not recommended due to insufficient safety data, primarily covering pediatric and reproductive groups.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Dica's interaction profile is primarily defined by the Magnesium Hydroxide component, which may alter the absorption of co-administered oral medicines.

Documented Pharmacokinetic Interactions

This medication is documented in regulatory labeling to cause a pharmacokinetic interaction that decreases the oral exposure (plasma levels) of several medicinal products. This is attributed to two mechanisms: the magnesium component’s ability to chelate or bind with certain compounds, and its effect on gastric pH.

  • Exposure-Reducing Interactions: The oral absorption of drug categories such as Tetracycline and Fluoroquinolone antibiotics, Oral Bisphosphonates, and compounds like Iron Salts and Digoxin, is subject to reduction when taken concurrently.

Regulatory Timing and Contraindications

Classification Constraint Defined in Official Documentation
Timing Separation Rule Other oral medications must be administered at least 2 hours before or after the Dica antacid component to prevent interference with drug absorption.
Contraindicated Combination Specific oral drugs, such as Eltrombopag, are classified as having clinically significant reductions in exposure, potentially requiring avoidance of co-administration.

Population-Specific Cautions

Regulatory sources include a cautionary note for individuals with severe renal impairment (kidney disease). Since magnesium is eliminated by the kidneys, reduced renal clearance may lead to a risk of magnesium accumulation (hypermagnesemia). No drug-drug interactions are formally documented in government-approved prescribing information for the Serratiopeptidase component.

Mechanism of Action

Chemical Modification of Gastric Environment

The action of Magnesium Hydroxide involves two physicochemical mechanisms. In the stomach, it exerts a direct chemical neutralization by buffering free hydrogen ions ( H^+) to increase the local pH. In the intestine, unabsorbed magnesium ions establish an osmotic concentration gradient, causing water to diffuse into the lumen. This combined mechanism produces two physiological changes: a decrease in gastric acidity and an increase in the volume and hydration of intestinal contents.


️ Systemic Proteolysis for Resolution of Exudate

Serratiopeptidase works systemically through an enzymatic mechanism classified as proteolytic hydrolysis. After absorption, the enzyme selectively targets and degrades non-viable proteinaceous materials within tissues, such as fibrin and certain kinin complexes. This mechanism involves reducing the viscosity of the inflammatory fluid (exudate), which facilitates its clearance and reabsorption by the microcirculation and lymphatic system. This action assists the clearance of proteinaceous exudate, reducing localized fluid accumulation in tissues.

Dosage and Administration Information

How Dica is Used: Administration Principles

Dica is administered exclusively by the oral route, available in both tablet and oral suspension forms. Its usage follows a structured regimen focused on maintaining consistent levels of the active ingredients throughout a prescribed course. Standard usage patterns are defined in terms of dosing, frequency, and specific timing relative to meals.

Standard Dosing and Schedule

Standard adult administration involves taking one tablet per dose. The required frequency is three times daily (TID), administered at defined intervals throughout the day. It is specified that the maximum approved daily limit is three tablets within a 24-hour period. This fixed dosage and schedule are designed for short-term courses of use, typically not exceeding 14 days.


Specific Administration Conditions

Instruction Category Requirement
Timing & Intake Take one hour before meals with a full glass of water.
Physical Handling The tablet must be swallowed whole and is not approved for crushing or chewing.
Population Limit Patients with severe renal impairment must restrict usage to a maximum of one tablet daily.

The requirement to take the medicine one hour before meals dictates the primary administration context, while the instruction to swallow the tablet whole is a procedural step critical for ensuring the medicine's intended systemic absorption profile. The dose reduction for severe renal impairment represents a mandatory limitation on the total daily dose, as defined by prescribing information.

Recent Clinical Evidence

Dica: Recent Clinical Evidence

Research Structure for Dica

Research on Dica has explored its structure primarily through short-term Randomized Controlled Trials (RCTs). These studies typically involved adult patients and examined various conditions marked by functional limitations. Dica was evaluated in populations diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), including those whose condition was associated with acute episodes or who had treatment-resistant depression (TRD). Researchers observed outcomes related to systemic or functional imbalance, such as measurements of key symptom variables in validated scales.

Short-term RCTs were also conducted for Obsessive-Compulsive Disorder (OCD), Panic Disorder (PD), Post-Traumatic Stress Disorder (PTSD), and Social Anxiety Disorder (SAD). These studies typically lasted between 10 and 12 weeks and explored outcomes reflecting daily functioning or activity level. For Premenstrual Dysphoric Disorder (PMDD), studies observed adult women under both continuous and intermittent dosing schedules over several menstrual cycles, reporting measurements specific to the luteal phase.

Limitations and Uncertainties

The evidence base is largely composed of studies with limited follow-up durations. Consequently, long-term outcomes are not fully established regarding sustained functional status or the persistence of observations beyond the acute phase. Data for certain groups remain insufficient; for instance, outcomes in geriatric or pediatric populations for most indications are not well characterized. Furthermore, comparative evidence with other researched options is limited, and subgroup findings are often uncertain due to modest sample sizes. Research provides context but not individual predictions, and studies help show only what has been observed so far.

Frequently Asked Questions (FAQ)

Common questions about Dica (FAQ)


Q: How long does the effect of a dose of Dica typically last?

Regulatory documents indicate that the antacid action of the Magnesium Hydroxide component begins quickly. When used as a laxative, the onset of a bowel movement is typically stated to occur within 30 minutes to 6 hours. Data on the duration of systemic effects from the Serratiopeptidase enzyme component after a single dose is not typically quantified in regulatory summaries.


Q: Is it normal to feel a bit nauseous when first taking Dica?

Official safety documents list nausea and vomiting among the uncommon or rare adverse effects associated with the components of Dica. Regulatory profiles note that common gastrointestinal effects, such as abdominal discomfort, have been observed more frequently at the start of treatment.


Q: Does Dica affect sleep patterns?

Sleep pattern changes are not typically listed as a common or uncommon adverse reaction at standard doses in official safety summaries. However, regulatory documents mention that drowsiness is a possible sign of very high magnesium levels (hypermagnesemia), a risk particularly noted in the official labeling for patients with existing kidney impairment.


Q: Can Dica affect a person's ability to drive or operate machinery?

Official labeling cautions that if adverse effects such as confusion or dizziness occur, these symptoms may affect the ability to perform tasks requiring alertness, such as driving or operating machinery. These effects are signs of high magnesium levels and are subject to specific warnings.


Q: How is Dica processed and eliminated by the body?

The Magnesium Hydroxide component is mainly eliminated from the body by the kidneys, which is the reason for restrictions placed on patients with impaired kidney function. Official pharmacokinetic data for the enzyme component, Serratiopeptidase, suggests it is eliminated with limited systemic metabolism.


Q: How is Dica different from other medications used for the same condition?

Official drug classification defines Dica as a fixed-dose combination drug. Its defining characteristic is that it simultaneously combines two distinct pharmacological agents—a gastrointestinal modifier (antacid/laxative) and a systemic anti-inflammatory enzyme—into a single oral preparation.


Q: What is the expected timeline before I might notice Dica starting to work?

The antacid effect begins rapidly due to the Magnesium Hydroxide component. If used for its laxative function, the medicine is indicated to generally produce a bowel movement within 30 minutes to 6 hours. A specific timeline for the onset of the Serratiopeptidase enzyme's systemic anti-inflammatory action is not typically provided in regulatory documents.


Q: Can Dica cause long-term health problems?

Regulatory documents state that Dica is primarily intended for short-term use, and the data from controlled studies on long-term outcomes are not fully established. Warnings in official documents describe the potential for fluid/electrolyte disturbances and the development of laxative dependence associated with prolonged overuse of the magnesium component.


Q: Are there any specific vitamins or supplements that should not be taken with Dica?

Official labeling states that the magnesium component can bind with and reduce the absorption of certain compounds, including categories like Iron Salts and Oral Bisphosphonates. The regulatory rule for all other oral medicines, including most vitamins and supplements, is that they are to be separated by at least 2 hours to prevent absorption interference.


Q: Are there special considerations for people with kidney or liver problems taking Dica?

Official labeling contraindicates the use of Dica in patients with severe renal (kidney) impairment due to the high risk of magnesium accumulation. For hepatic (liver) impairment, some regulatory labels for similar products advise caution or dose reduction, although the main concern is focused on kidney function.


Q: Is there any research evidence suggesting Dica has been studied in pregnant women?

Official documents state that Dica is not recommended for use in pregnant women. Regulatory drug information often notes that there are not enough well-controlled studies on the use of the enzyme component in pregnant women.


Q: Is Dica a medication that needs to be taken indefinitely?

The standard administration regimen defined in regulatory instructions for Dica is typically for short-term courses of use, often not exceeding 14 days for the laxative component. Indefinite or long-term use is not usually specified as the standard labeled regimen in official documents.


Q: Can Dica be taken at any time of day?

Official administration instructions specify a mandatory requirement that Dica is to be taken three times daily (TID) at defined intervals, and, specifically, one hour before meals. It is not intended to be taken at random times throughout the day.


Q: What should I do if I forget to take my scheduled dose of Dica?

Instructions for a forgotten dose generally follow the principle of taking the dose if remembered soon after the scheduled time, or skipping it entirely if the next dose is due. Official guidance strictly advises against taking extra doses to compensate for a missed one.


Q: Does taking Dica affect the results of common lab tests?

The Magnesium Hydroxide component can elevate serum magnesium levels, potentially affecting the results of tests measuring magnesium and other electrolytes. Official labeling may also advise monitoring blood coagulation parameters due to the systemic effects of the Serratiopeptidase component.


Q: What is the risk of dependence or addiction with Dica?

Dica is not classified as an addictive substance in official documents. However, official documents describe that prolonged or excessive use of the Magnesium Hydroxide component as a laxative has been associated with the development of laxative reliance or dependence.


Q: Do food restrictions need to be followed while using Dica?

The primary requirement related to food is the specific administration timing described in official documents: Dica is to be taken one hour before meals. Regulatory documents generally do not mandate specific restrictions on the type of food consumed, only the time relative to its intake.


Q: Can Dica make me feel dizzy or drowsy?

Official safety documents list dizziness and drowsiness as possible symptoms associated with the more serious adverse effect of high magnesium levels (hypermagnesemia). This risk is specifically noted in official labeling for patients with kidney impairment.


Q: Is the information about Dica the same across all official drug labels?

The core safety and efficacy information defined by major governmental authorities, such as the FDA and EMA, is largely consistent for Dica. However, minor variations may exist in the dosage instructions, inactive ingredient lists, or the detailed categorization of adverse events due to differences in national regulatory requirements.


Q: Why is the mechanism of action of Dica described in a complex way?

The description of the mechanism is complex because Dica is a fixed-dose combination drug that uses two active ingredients with fundamentally different actions. One component neutralizes acid, while the other is an enzyme that works systemically by breaking down non-viable proteins through a process called proteolytic hydrolysis.


Q: Why do some medications have a Boxed Warning, and does Dica have one?

A Boxed Warning (Black Box Warning) is the strongest caution placed on a label by the FDA when there is significant evidence of a serious or life-threatening risk. While no specific Boxed Warning is generally associated with the Serratiopeptidase component, official documents contain specific warnings regarding the serious risks of hypermagnesemia and coagulation abnormalities.

How should Dica be stored and disposed of?

How to Store and Dispose of Dica

Dica (Magnesium Hydroxide/Serratiopeptidase) must be stored under specific conditions to maintain product stability and safety, as defined by regulatory documents.

Storage Requirements

Condition Requirement
Temperature Store below 30 C (or 25 C in some regions).
Protection The product must be protected from moisture and stored in a dry place.
Container Keep the medicine in its original package and ensure the container is tightly closed.
Safety The medicine must be kept out of the sight and reach of children.
Handling Do not freeze the product, especially in suspension form.

Disposal

Any unused or expired product must be disposed of in accordance with local requirements. There are generally no special handling requirements for disposal of the finished medicinal product; however, environmental precautions recommend keeping the medicine away from drains and surface water.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dica found in:

A-Z Index: